Park Home Owners

Debate between Chris Coghlan and Clive Jones

Tuesday 28th April 2026 Westminster Hall

[Clive Jones (Wokingham) (LD)]

It is a pleasure to serve under your chairship, Sir Alec. I congratulate the hon. Member for Rushcliffe (James Naish) for securing this important debate.

There are six park home estates in my constituency. They provide vital accommodation and a strong sense of community among residents who take pride in their homes and their estates. This debate raises a fundamental issue of fairness. Many of my park home residents are retirees, often on fixed incomes. Many downsize into park homes precisely to release equity, reduce costs and secure greater financial stability. When they come to sell their home, the requirement to hand over 10% of the sale price to the site owner causes real distress.

[Chris Coghlan]

Park home owners in my constituency tell me that site owners have pressured them into selling, in order to get that 10% commission. Does my hon. Friend agree that that is wrong and that the 10% commission should be abolished?

[Clive Jones]

I agree 100%. It is not a small administrative fee: it can amount to tens of thousands of pounds. That charge exists outside the protections that most homeowners take for granted. In the mainstream housing market, sellers are protected by competition and choice. Estate agent fees are negotiated. Services must be delivered to justify the costs and, if someone does not like the terms, they can walk away. Park home residents do not have that freedom.

We would not accept this in any other part of the housing system—we would not accept a mandatory 10% charge simply for the right to sell our own homes. People delay moving closer to their families and put off downsizing further. Even when their health declines, some remain in homes that no longer meet their needs simply because they cannot afford to lose such a large portion of their asset. No group of homeowners should face a system that strips away rights and imposes disproportionate financial penalties.

It is time to bring fairness back into the system. That is why I support the PHOJC’s calls for the 10% charge to be ended without delay or replaced with a fairer system that does not penalise residents. Changes should also be made to ensure that park home residents have the same protection and fair treatment as all other homeowners, bringing park home living in line with normal consumer and housing rights.

Less Survivable Cancers

Debate between Chris Coghlan and Clive Jones

Tuesday 6th January 2026 Westminster Hall

[Clive Jones]

The hon. Member makes a good point; we definitely need more clinical trials in this country. We have been lagging behind in the last few years, and we need them nationally, rather than just in Scotland, Wales, England or Northern Ireland. That would be advantageous for both drug companies and the people who benefit from those trials.

For many of these less survivable cancers, survival rates in the UK lag behind other countries. We can see from our international counterparts, including Australia, Belgium, Denmark and the US, that progress is achievable, and that system reforms can play a key role in driving better patient outcomes. For example, the UK is ranked 29th out of 33 countries for pancreatic cancer survival. It is fair to ask the Minister: why is the UK ranked so low? It is also fair to ask the Conservative shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson): why are we ranked so low after the Conservatives’ 14 years in Government? Perhaps it is due to the challenges in how our healthcare and cancer services are organised, and our service delivery, rather than the availability of treatment options. It is vital that we learn from our international counterparts and understand what systemic changes they have made to drive progress.

The all-party parliamentary group on less survivable cancers, of which I am a member, launched an inquiry into earlier detection and faster diagnosis. During the inquiry, the APPG heard from people with lived experience—clinicians, researchers, charities and the industry—about what vital measures are needed in the national cancer plan to improve earlier detection and faster diagnosis. The APPG found that if earlier diagnosis rates were doubled, an additional 7,500 lives would be saved every year. Deaths from those cancers could quickly be reduced by 10%.

Faster diagnosis is integral to saving lives and improving outcomes for people impacted by less survivable cancers. Simply put, it enables patients to access treatment and care much quicker, increasing their chances of survival. We are currently far from achieving this: just 28% of less survivable cancers are diagnosed at stages 1 or 2, compared with 54% for all other cancers. Concerningly, brain tumours are diagnosed in emergency settings, which is closely linked to worse outcomes.

That is common for myeloma patients—an incurable blood cancer. A third of people with myeloma are diagnosed via emergency presentation. Like the delay in diagnosing less survivable cancers, this means that their cancer has progressed untreated, and the condition has become more advanced, so their ability to tolerate treatments may be seriously hampered. The APPG’s inquiry produced some recommendations for the Government that illustrate the broad range of actions needed to achieve earlier detection and faster diagnosis, from equipping GPs with better tools and rolling out targeted screening programmes to promoting greater research into innovative diagnostics.

[Chris Coghlan (Dorking and Horley) (LD)]

I commend my hon. Friend for securing this invaluable debate. My constituent Billy was just four years old when he passed away due to DIPG—diffuse intrinsic pontine glioma—which is an incurable child brain tumour cancer. Every nine days a child is diagnosed with it. At the request of Billy’s parents I asked the Government whether there was any more they could do for brain cancer research. I am delighted that the Government have since announced that they have allocated £13.7 million in funding to the National Institute for Health and Care Research brain tumour research consortium. Does my hon. Friend agree that allocating research into rarer cancers not only benefits the children who suffer from these horrific diseases but enhances our research and development capability more broadly, clinically, which is also a vital industry for the UK?